Pfizer (PFE) Goodwill & Intangibles (2009 - 2026)

Pfizer (PFE) has reported Goodwill & Intangibles for 18 consecutive years, with $118.5 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Goodwill & Intangibles fell 2.65% year-over-year to $118.5 billion in Q2 2026; TTM through Jun 2026 was $118.5 billion, a 2.65% decrease from a year earlier, with the FY2025 full-year figure at $125.0 billion, up 0.85% from the prior year.
• Goodwill & Intangibles was $118.5 billion for Q2 2026 at Pfizer, down from $124.0 billion in the prior quarter.
• Over five years, Goodwill & Intangibles peaked at $132.7 billion in Q4 2023 and troughed at $79.0 billion in Q3 2022.
• A 5-year average of $113.7 billion and a median of $122.1 billion in 2025 frame the typical range for Goodwill & Intangibles.
• Across the five-year window, Goodwill & Intangibles jumped 41.34% in 2024 and slipped 7.35% in 2025, its largest moves.
• Over 5 years, Goodwill & Intangibles stood at $94.7 billion in 2022, then soared by 40.04% to $132.7 billion in 2023, then dropped by 6.59% to $123.9 billion in 2024, then gained by 0.85% to $125.0 billion in 2025, then slipped by 5.22% to $118.5 billion in 2026.
• The last three Goodwill & Intangibles figures came in at $118.5 billion (Q2 2026), $124.0 billion (Q1 2026), and $125.0 billion (Q4 2025), per Business Quant data.